文献速递精神分裂症与精神病性障碍

呫诺美林-曲司氯铵治疗精神分裂症的疗效与安全性:一项随机临床试验

Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

EMERGENT-3是一项3期多中心随机双盲安慰剂对照5周试验,纳入256例急性精神病性发作的精神分裂症成人患者,比较呫诺美林-曲司氯铵与安慰剂的疗效和安全性。第5周时,呫诺美林-曲司氯铵组PANSS总分较基线的降幅显著大于安慰剂组(-20.6 vs -12.2,最小二乘均值差-8.4,95%CI -12.4至-4.3,P<.001,Cohen d效应量0.60)。因治疗中出现的不良事件而停药的比例两组相似,最常见不良事件为恶心、消化不良、呕吐和便秘。

要点

  • 呫诺美林-曲司氯铵第5周PANSS总分降幅显著大于安慰剂(-20.6 vs -12.2,差值-8.4,P<.001)。
  • 因不良事件停药比例两组相似:呫诺美林-曲司氯铵组8例(6.4%)vs 安慰剂组7例(5.5%)。
  • 常见不良事件为恶心、消化不良、呕吐和便秘,呫诺美林-曲司氯铵组发生率高于安慰剂组。

核心结论

  • 呫诺美林-曲司氯铵对急性精神病性发作的精神分裂症患者有效且耐受性良好。
  • 结合EMERGENT-1和EMERGENT-2试验的一致结果,呫诺美林-曲司氯铵有望成为首个无D2多巴胺受体阻断活性的新型抗精神病药物。

研究设计与样本

  • EMERGENT-3(NCT04738123)是一项3期、多中心、随机、双盲、安慰剂对照的5周试验。
  • 研究对象为经历急性精神病性发作的精神分裂症患者,于2021年4月1日至2022年12月7日在美国和乌克兰的30个住院点开展。
  • 共256例参与者按1:1随机分配至呫诺美林-曲司氯铵组(125例)或安慰剂组(131例),呫诺美林-曲司氯铵最大剂量为呫诺美林125 mg/曲司氯铵30 mg,治疗5周。
  • 参与者平均(SD)年龄43.1(11.8)岁,男性191例(74.6%),黑人或非裔美国人156/256例(60.9%),白人98例(38.3%),亚裔1例(0.4%)。
  • 数据于2023年2月至6月进行分析。

主要发现

  • 第5周时,呫诺美林-曲司氯铵组PANSS总分较基线降低20.6,安慰剂组降低12.2,最小二乘均值差为-8.4(95%CI -12.4至-4.3,P<.001,Cohen d效应量0.60)。
  • 因治疗中出现的不良事件而停药的比例:呫诺美林-曲司氯铵组8例(6.4%)vs 安慰剂组7例(5.5%)。
  • 呫诺美林-曲司氯铵组 vs 安慰剂组最常见治疗中出现的不良事件:恶心24例(19.2%)vs 2例(1.6%),消化不良20例(16.0%)vs 2例(1.6%),呕吐20例(16.0%)vs 1例(0.8%),便秘16例(12.8%)vs 5例(3.9%)。
  • 锥体外系症状、体重增加和嗜睡的测量指标在治疗组间相似。

关键数值与推荐

  • 主要终点为第5周PANSS总分较基线的变化。
  • 次要终点包括第5周PANSS阳性分量表评分、PANSS阴性分量表评分、PANSS Marder阴性因子评分、临床总体印象-严重程度评分较基线的变化,以及PANSS总分降低至少30%的参与者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A significant need exists for new antipsychotic medications with different mechanisms of action, greater efficacy, and better tolerability than existing agents. Xanomeline is a dual M1/M4 preferring muscarinic receptor agonist with no direct D2 dopamine receptor blocking activity. KarXT combines xanomeline with the peripheral muscarinic receptor antagonist trospium chloride with the goal of reducing adverse events due to xanomeline-related peripheral muscarinic receptor activation. In prior trials, xanomeline-trospium chloride was effective in reducing symptoms of psychosis and generally well tolerated in people with schizophrenia. OBJECTIVE: To evaluate the efficacy and safety of xanomeline-trospium vs placebo in adults with schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: EMERGENT-3 (NCT04738123) was a phase 3, multicenter, randomized, double-blind, placebo-controlled, 5-week trial of xanomeline-trospium in people with schizophrenia experiencing acute psychosis, conducted between April 1, 2021, and December 7, 2022, at 30 inpatient sites in the US and Ukraine. Data were analyzed from February to June 2023. INTERVENTIONS: Participants were randomized 1:1 to receive xanomeline-trospium chloride (maximum dose xanomeline 125 mg/trospium 30 mg) or placebo for 5 weeks. MAIN OUTCOMES AND MEASURES: The prespecified primary end point was change from baseline to week 5 in Positive and Negative Syndrome Scale (PANSS) total score. Secondary outcome measures were change from baseline to week 5 in PANSS positive subscale score, PANSS negative subscale score, PANSS Marder negative factor score, Clinical Global Impression-Severity score, and proportion of participants with at least a 30% reduction in PANSS total score. Safety and tolerability were also evaluated. RESULTS: A total of 256 participants (mean [SD] age, 43.1 [11.8] years; 191 men [74.6%]; 156 of 256 participants [60.9%] were Black or African American, 98 [38.3%] were White, and 1 [0.4%] was Asian) were randomized (125 in xanomeline-trospium group and 131 in placebo group). At week 5, xanomeline-trospium significantly reduced PANSS total score compared with placebo (xanomeline-trospium , -20.6; placebo, -12.2; least squares mean difference, -8.4; 95% CI, -12.4 to -4.3; P < .001; Cohen d effect size, 0.60). Discontinuation rates due to treatment-emergent adverse events (TEAEs) were similar between the xanomeline-trospium (8 participants [6.4%]) and placebo (7 participants [5.5%]) groups. The most common TEAEs in the xanomeline-trospium vs placebo group were nausea (24 participants [19.2%] vs 2 participants [1.6%]), dyspepsia (20 participants [16.0%] vs 2 participants [1.6%]), vomiting (20 participants [16.0%] vs 1 participant [0.8%]), and constipation (16 participants [12.8%] vs 5 participants [3.9%]). Measures of extrapyramidal symptoms, weight gain, and somnolence were similar between treatment groups. CONCLUSIONS AND RELEVANCE: Xanomeline-trospium was efficacious and well tolerated in people with schizophrenia experiencing acute psychosis. These findings, together with the previously reported and consistent results from the EMERGENT-1 and EMERGENT-2 trials, support the potential of xanomeline-trospium to be the first in a putative new class of antipsychotic medications without D2 dopamine receptor blocking activity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04738123.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kaul I, Sawchak S, Walling DP, et al. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2024. PMID: 38691387. doi:10.1001/jamapsychiatry.2024.0785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。